ID   RBL15
AC   CVCL_S618
SY   RBL-15
DR   DSMZ; ACC-943
DR   Wikidata; Q54949353
RX   PubMed=2090524;
RX   PubMed=2365495;
RX   PubMed=7959682;
RX   PubMed=25326674;
RX   PubMed=30584916;
CC   Doubling time: 8 days (PubMed=2365495); 45 hours (PubMed=25326674); ~5-7 days (DSMZ=ACC-943).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9884; RB1; Zygosity=Homozygous (PubMed=25326674).
CC   Derived from site: In situ; Eye; UBERON=UBERON_0000970.
ST   Source(s): DSMZ=ACC-943
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12,13
ST   D16S539: 11
ST   D18S51: 12,18
ST   D19S433: 12,15
ST   D21S11: 29,30
ST   D2S1338: 19,21
ST   D3S1358: 15,18
ST   D5S818: 11,13
ST   D7S820: 8,9
ST   D8S1179: 10,13
ST   FGA: 21,23
ST   Penta D: 11,13
ST   Penta E: 12,13
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C8713; Bilateral retinoblastoma
DI   ORDO; Orphanet_790; Retinoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   11M
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 15
//
RX   PubMed=2090524; DOI=10.1111/j.1432-0436.1990.tb00479.x;
RA   Griegel S., Heise K., Kindler-Rohrborn A., Rajewsky M.F.;
RT   "In vitro differentiation of human retinoblastoma cells into neuronal
RT   phenotypes.";
RL   Differentiation 45:250-257(1990).
//
RX   PubMed=2365495; DOI=10.1002/ijc.2910460123;
RA   Griegel S., Hong C., Frotschl R., Hulser D.F., Greger V.,
RA   Horsthemke B., Rajewsky M.F.;
RT   "Newly established human retinoblastoma cell lines exhibit an
RT   'immortalized' but not an invasive phenotype in vitro.";
RL   Int. J. Cancer 46:125-132(1990).
//
RX   PubMed=7959682; DOI=10.1007/BF00211013;
RA   Greger V., Debus N., Lohmann D.R., Hopping W., Passarge E.,
RA   Horsthemke B.;
RT   "Frequency and parental origin of hypermethylated RB1 alleles in
RT   retinoblastoma.";
RL   Hum. Genet. 94:491-496(1994).
//
RX   PubMed=25326674; DOI=10.1007/s00418-014-1285-z;
RA   Busch M.A., Philippeit C., Weise A., Dunker N.;
RT   "Re-characterization of established human retinoblastoma cell lines.";
RL   Histochem. Cell Biol. 143:325-338(2015).
//
RX   PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018;
RA   Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T.,
RA   Schramm A., Temming P., Steenpass L.;
RT   "Comprehensive characterization of RB1 mutant and MYCN amplified
RT   retinoblastoma cell lines.";
RL   Exp. Cell Res. 375:92-99(2019).
//